SITC 2023 Comparison of Blinatumomab and Biosimilar CD19xCD3 BiTE responses in PBMC-Humanized Mice Used as a Preclinical Lymphoma Mouse Mode
Read Flipbook
JAX strives to accelerate your drug development process and unblock preclinical bottlenecks. Explore these resources to learn how JAX can help you make informed decisions unique to your oncology research needs. Want to connect? Schedule a meeting with a JAX representative!
Error - something went wrong!
Let JAX know about your Immuno-Oncology needs!
Thank you! We will be in touch soon.